🇺🇸 FDA

Company profile · Sponsor

ALTERITY

ALTERITY THERAPEUTICS LTD

ATHE · NYSE pharma MELBOURNE, USA
Pipeline
3
Drugs
0
Patents
4

Quick answer

ALTERITY (ATHE) is a pharma company. headquartered in MELBOURNE, USA. listed on NYSE. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 4 patents to this profile..

Company facts

Ticker ATHE
Exchange NYSE
Company type pharma
Headquarters MELBOURNE, USA
SEC CIK 0001131343

Pipeline (3)

Search pipeline →

  1. ATH434

    ALTERITY

    Multiple System Atrophy

    phase 2 small molecule completed

    1 trial

  2. ATH434 dose level 1

    ALTERITY

    Multiple System Atrophy

    phase 2 small molecule completed

    1 trial

  3. ATH434-DP2

    ALTERITY

    Multiple System Atrophy

    phase 2 small molecule active

    1 trial

Patents (4)

Search patents →

  1. US 11603364

    Acyl hydrazone derivative compounds for treating disease

    Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11357770

    Method of treating immunoglobulin light chain amyloidosis

    Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11155547

    Compounds for and methods of treating diseases

    Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10941143

    Imidazo [1,5-a]pyridine compounds and their use

    Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is ALTERITY?

ALTERITY (ATHE) is a pharma company. headquartered in MELBOURNE, USA. listed on NYSE. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 4 patents to this profile..

What pipeline programs does ALTERITY sponsor?

We track 3 ClinicalTrials.gov-linked programs for ALTERITY, including ATH434 and 2 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does ALTERITY company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.